Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386811 | 0.90 | KDR (0.44) | NAMPTFLT1ABCG2KDRMEN1 | |
| SCHEMBL1386339 | 0.89 | KDR (0.48) | PLK1NAMPTFLT1ABCG2KDR | |
| SCHEMBL1383042 | 0.88 | KIF11 (0.53) | NAMPTFLT1ABCG2KDRMEN1 | |
| SCHEMBL1382926 | 0.87 | FLT1 (0.46) | FLT1ABCG2KDRMEN1KMT2A | |
| SCHEMBL13955447 | 0.86 | ABL1 (0.56) | EPHX2FLT1KDRRAB9AABL1 | |
| SCHEMBL1383504 | 0.86 | KDR (0.44) | NAMPTFLT1KDRMEN1KMT2A | |
| SCHEMBL1383724 | 0.86 | KDR (0.53) | NAMPTFLT1ABCG2KDRMEN1 | |
| SCHEMBL1385235 | 0.86 | NAMPT (0.46) | NAMPTFLT1KDRMEN1KMT2A | |
| SCHEMBL1382851 | 0.85 | FLT1 (0.60) | NAMPTFLT1KDRMEN1KMT2A | |
| SCHEMBL1387032 | 0.84 | KDR (0.54) | NAMPTFLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603566-B1 | USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES | NOVARTIS AG (CH) | 2009-01-21 | — | — | EP | disclosed |